These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38883150)

  • 1. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention.
    Pope J; Finckh A; Silva-Fernández L; Mandl P; Fan H; Rivas JL; Valderrama M; Montoro M
    Open Access Rheumatol; 2024; 16():115-126. PubMed ID: 38883150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
    Fleischmann R; Wollenhaupt J; Takiya L; Maniccia A; Kwok K; Wang L; van Vollenhoven RF
    RMD Open; 2017; 3(2):e000491. PubMed ID: 29435359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
    Fleischmann R; Haraoui B; Buch MH; Gold D; Sawyerr G; Shi H; Diehl A; Lee K
    Rheumatol Ther; 2023 Apr; 10(2):375-386. PubMed ID: 36534208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
    Wright GC; Mysler E; Kwok K; Cadatal MJ; Germino R; Yndestad A; Kinch CD; Ogdie A
    Rheumatol Ther; 2024 Jul; ():. PubMed ID: 38958913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
    Mueller RB; Schulze-Koops H; Furst DE; Cohen SB; Kwok K; Wang L; Killeen T; von Kempis J
    Clin Rheumatol; 2022 Apr; 41(4):1045-1055. PubMed ID: 34973077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
    Smolen JS; Aletaha D; Gruben D; Zwillich SH; Krishnaswami S; Mebus C
    Arthritis Rheumatol; 2017 Apr; 69(4):728-734. PubMed ID: 27907269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.
    Cohen SB; Pope J; Haraoui B; Irazoque-Palazuelos F; Korkosz M; Diehl A; Rivas JL; Lukic T; Liu S; Stockert L; Iikuni N; Keystone EC
    Lancet Rheumatol; 2019 Sep; 1(1):e23-e34. PubMed ID: 38229356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
    Citera G; Jain R; Irazoque F; Madariaga H; Gruben D; Wang L; Stockert L; Santana K; Ebrahim A; Ponce de Leon D
    Rheumatol Ther; 2024 Feb; 11(1):35-50. PubMed ID: 37925660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
    Strand V; Kavanaugh A; Kivitz AJ; van der Heijde D; Kwok K; Akylbekova E; Soonasra A; Snyder M; Connell C; Bananis E; Smolen JS
    Rheumatol Ther; 2018 Dec; 5(2):341-353. PubMed ID: 29761420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
    Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
    Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
    Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
    Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
    Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
    Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
    Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
    Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
    Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.